ALVR

AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference

AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses

Positive Phase 2 Proof-of-Concept Data for Viralym-M and Burden of Disease Data Presented in Oral Presentations at the 62nd American Society of Hematology Annual Meeting

Preclinical Data Demonstrate Anti-Viral Activity of AlloVir's ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy

AlloVir Announces Oral Data Presentations at 62nd American Society of Hematology Annual Meeting

AlloVir prices upsized IPO at $17, to be valued at over $1 billion